We look beyond DNA to see cancer with new clarity.
Our first product–the Avantect Pancreatic Cancer Test–is a test for patients at high risk for pancreatic cancer, including those newly diagnosed with type 2 diabetes age 50+. The Avantect test detects pancreatic cancer in its earliest stages by measuring levels of the biomarker 5-hydroxymethylcytosine (5hmC) using a simple blood draw. Pancreatic cancer is one of the deadliest cancers, because it is often diagnosed too late for patients to receive effective treatment and patients newly diagnosed with type 2 diabetes are 8 times as likely to develop pancreatic cancer as the general population.
We are also developing targeted multi-cancer test panels to detect several different cancers through a single blood draw.